ATE303820T1 - Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut - Google Patents

Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut

Info

Publication number
ATE303820T1
ATE303820T1 AT00993688T AT00993688T ATE303820T1 AT E303820 T1 ATE303820 T1 AT E303820T1 AT 00993688 T AT00993688 T AT 00993688T AT 00993688 T AT00993688 T AT 00993688T AT E303820 T1 ATE303820 T1 AT E303820T1
Authority
AT
Austria
Prior art keywords
treatment
angiogenic factor
vector encoding
vascularization
cornea
Prior art date
Application number
AT00993688T
Other languages
English (en)
Inventor
Marc Abitbol
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9916780A external-priority patent/FR2803207B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE303820T1 publication Critical patent/ATE303820T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Eyeglasses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
AT00993688T 1999-12-30 2000-12-21 Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut ATE303820T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9916780A FR2803207B1 (fr) 1999-12-30 1999-12-30 Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
US21769100P 2000-07-12 2000-07-12
PCT/FR2000/003653 WO2001049316A2 (fr) 1999-12-30 2000-12-21 Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes

Publications (1)

Publication Number Publication Date
ATE303820T1 true ATE303820T1 (de) 2005-09-15

Family

ID=26235200

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00993688T ATE303820T1 (de) 1999-12-30 2000-12-21 Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut

Country Status (9)

Country Link
US (1) US20080107714A1 (de)
EP (1) EP1246642B1 (de)
JP (1) JP2004500369A (de)
AT (1) ATE303820T1 (de)
AU (1) AU2857401A (de)
DE (1) DE60022549T2 (de)
DK (1) DK1246642T3 (de)
ES (1) ES2245656T3 (de)
WO (1) WO2001049316A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076454A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
JP4855782B2 (ja) * 2006-01-13 2012-01-18 株式会社シード 眼の遺伝子治療に用いられるハイドロゲル製眼用レンズ
RU2440620C1 (ru) * 2010-06-17 2012-01-20 Государственное образовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ моделирования неоваскуляризации роговицы

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710796A (en) * 1971-05-14 1973-01-16 C Neefe Corneal drug delivery method
US5800820A (en) * 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
WO1999029856A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Restin and methods of use thereof

Also Published As

Publication number Publication date
EP1246642B1 (de) 2005-09-07
DE60022549D1 (de) 2005-10-13
AU2857401A (en) 2001-07-16
EP1246642A2 (de) 2002-10-09
WO2001049316A3 (fr) 2002-05-23
DE60022549T2 (de) 2006-05-18
US20080107714A1 (en) 2008-05-08
JP2004500369A (ja) 2004-01-08
WO2001049316A2 (fr) 2001-07-12
ES2245656T3 (es) 2006-01-16
DK1246642T3 (da) 2006-01-09

Similar Documents

Publication Publication Date Title
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE59902314D1 (de) Oligomerisiertes Organopolysiloxan-Cokondensat, dessen Herstellung und dessen Verwendung zur Behandlung von Oberflächen
DE60121808D1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
DE69533697D1 (de) ANTISENSE OLIGONUKLEOTIDMODULATION DER raf GENEXPRESSION
DE69527847D1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE230607T1 (de) Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE69939956D1 (de) Verwendung von Myoblasten zur Herstellung eines Medikaments zur Behandlung der stressbedingten Harninkontinenz
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
EP1023005A4 (de) Verfahren zum beschichten von stents mit dna sowie zur in vivo expression von rekombinanten genen von mit dna beschichteten
DE60219658D1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
ATE370738T1 (de) Verwendung von eplerenon zur behandlung von restenose
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE504600T1 (de) Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
DE60022549D1 (de) Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut
DE60100660D1 (de) Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
ATE273711T1 (de) Verwendung von niedermolekularem heparin zur behandlung und/oder prophylaxe motoneuronaler krankheiten
ATE360425T1 (de) Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE258064T1 (de) Verwendung von antileukoprotease zur behandlung von endometriose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1246642

Country of ref document: EP